Deborah Dunsire, Lundbeck CEO
November 12, 2021 07:04 AM ESTUpdated 07:19 AM
Pharma

Cit­ing mi­graine drug growth and pan­dem­ic, Lund­beck to cut 300 jobs and close In­dia fa­cil­i­ty

Max Gelman

Senior Editor

The Dan­ish bio­phar­ma Lund­beck has seen its fair share of R&D set­backs over the years but it’s tak­en pride in Vyep­ti, the CGRP mi­graine drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times